The processes associated with transition to castration independent prostate cancer growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress. It is often overcome in malignant transformation to confer a survival advantage. CCAAT/Enhancer Binding Protein (C/EBP) β function is frequently deregulated in human malignancies and interestingly, androgen dependent prostate cancer cells express primarily the LIP isoform. We found that C/EBPβ expression is negatively regulated by androgen receptor activity and that treatment of androgen dependent cell lines with anti-androgens increases C/EBPβ mRNA and protein levels. Accordingly, we also find that C/EBPβ levels are significantly elevated in primary prostate cancer samples from castration resistant compared with therapy naive patients. Chromatin immunoprecipitation demonstrated enhanced binding of the androgen receptor to the proximal promoter of the CEBPB gene in the presence of dihydroxytestosterone. Upon androgen deprivation, induction of C/EBPβ is facilitated by active transcription as evident by increased histone 3 acetylation at the C/EBPβ promoter. Also, the androgen agonist R1881 suppresses the activity of a CEBPB promoter reporter. Loss of C/EBPβ expression prevents growth arrest following androgen deprivation or anti-androgen challenge. Accordingly, suppression of C/EBPβ under low androgen conditions results in reduced expression of senescence-associated secretory genes, significantly decreased number of cells displaying heterochromatin foci, and increased numbers of Ki67 positive cells. Ectopic expression of C/EBPβ caused pronounced morphological changes, reduced PC cell growth, and increased the number of senescent LNCaP cells. Lastly, we found that senescence contributes to prostate cancer cell survival under androgen deprivation, and C/EBPβ deficient cells were significantly more susceptible to killing by cytotoxic chemotherapy Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use
Introduction
Prostate cancer (PC) is the most prevalent malignancy in adult men in the United States. 1 Although early detection and treatment of localized disease is often curative, PC remains a leading cause of cancer death. Anti-androgen therapy is the most effective approach in patients with advanced disease and induces significant responses in almost all patients. 2 However, androgen deprivation achieved by pharmacologic or surgical castration results in only limited apoptosis of tumor cells 3 , 4 and accordingly only partial tumor regression.
Indeed after a period of disease control most patients develop castration resistant growth and PC progression, which is responsible for the majority of the morbidity and mortality associated with this disease. 2 Identifying mechanisms that engender castration resistance is crucial for the design of future therapeutic strategies. Progress has been made understanding the mechanisms associated with eventual emergence of castration resistant prostate cancer (CRPC). However, less is known about the early adaptation associated with androgen deprivation. 5 -7 Members of the CCAAT/enhancer binding protein (C/EBP) family of transcription factors are characterized by a conserved C-terminus, which contains both a DNA-binding basic region (BR) and leucine-zipper (LZ), collectively referred to as the bZIP domain. C/EBPβ is a widely expressed transcription factor that promotes proliferation or terminal differentiation and growth arrest in several different cell types. 8 These opposing functions seem to be regulated by the expression of different C/EBPβ translational isoforms from three in frame start codons within an intron-less mRNA. 9 , 10 The two high molecular weight C/EBPβ isoforms, termed liver-enriched activating proteins (LAP and LAP*), contain N-terminal transactivation domains (TAD), whereas the liver-enriched inhibitory protein (LIP) lacks these TADs. LIP can dominantly inhibit LAPs and other C/EBP members via heterodimerization or by recruiting transcriptional repressors. 11 C/EBPβ activity affects several facets of PC disease progression. C/EBPβ regulates the expression of steroidogenic genes including StAR and cytochrome p450 aromatase, 12 , 13 and its activity is modulated in response to dihydrotestosterone, estrogen and progesterone. 14 -17 It has also been suggested that C/EBPβ can act as a co-repressor of the androgen receptor (AR) in PC. 18 , 19 Although C/EBPβ is not detected in healthy prostate, luminal epithelial cells up-regulate C/EBPβ in the case of proliferative-inflammatory atrophy, a precursor to PC, 20 and C/EBPβ participates in the regulation of metastatic genes and PC cell survival. 21 , 22 However, the contribution of C/EBPβ to the emergence of castration resistant growth has not been previously investigated.
Cellular senescence is a stable cell cycle arrest that occurs in response to a variety of intrinsic and extrinsic sublethal stress stimuli. 23 , 24 Accumulating data point to an important role of senescence in cancer progression. 23 , 24 Recently, several groups demonstrated that in response to androgen deprivation PC cells undergo senescence, and that the acquisition of senescence is associated with emergence of castrate resistant growth. 5 -7 In other lineages C/ EBPβ and its downstream target genes are critical for the induction and maintenance of oncogene induced senescence, associated with over-expression of activated Ras or BRAF. 8 , 25 , 26 C/EBPβ can directly bind to target gene promoters and enhancers to induce senescence-associate factors IL-6 and IL-8, but can also suppress E2F-1 target genes and induce growth arrest dependent on E2F:pRb. 8 We now demonstrate that upon androgen deprivation C/EBPβ is rapidly up-regulated in androgen dependent PC cells and that AR binds to and suppresses the C/EBPβ proximal promoter. Increased expression of C/EBPβ under these conditions is necessary for acquisition of the senescent phenotype. Accordingly, preventing C/EBPβ up-regulation increases the susceptibility of PC cells to apoptosis induced by chemotherapy.
Results

CRPC is associated with increased CEBPB
To determine whether C/EBPβ levels correlate with human prostate cancer progression we interrogated the Oncomine database. 27 In the Grasso et al data set 28 that included gene expression patterns from 28 benign prostate tissues, 59 localized PC, and 35 CRPC samples CEBPB expression was significantly (p<1.9 × 10 −6 ) elevated in CRPC compared with localized disease (Figures 1a, 1b) .
Inhibition of AR induces CEBPB transcription
Treatment of LNCaP cells with the synthetic AR agonist R1881 for 24 hrs results in a dosedependent 2.5-fold decrease in CEBPB mRNA and protein expression (Figures 2a, 2b) , and as expected, prostate specific antigen (PSA) transcript levels increased under these conditions. Conversely, culturing LNCaP cells in androgen depleted media (ADM) for 7 days resulted in a significant 3.8-fold increase in C/EBPβ expression ( Figure 2c ). Pharmacologic inhibition of the AR using bicalutamide resulted in a dose dependent rise in CEBPB transcript abundance, achieving a 7.5-fold increase at the highest dose tested ( Figure   2d ). Accordingly, we detected increased protein levels of C/EBPβ in both LNCaP and LAPC4 cells treated with bicalutamide, or flutamide ( Figure 2e ). Since bicalutamide, or flutamide may have an AR agonist effect we also tested the effect of enzalutamide, which does not have agonistic effects. Similar to bicalutamide, incubation with 20 μM enzalutamide resulted in increased C/EBPβ levels ( Figure 2f ). CEBPB RNA levels were rapidly up-regulated within 4 hrs of exposure of LNCaP cells to bicalutamide (Figure 2g ).
To assess binding of AR to the CEBPB promoter, LNCaP cells were cultured in full media and subjected to chromatin immunoprecipitation (ChIP) analysis. Precipitated DNA was amplified using primers spanning the proximal (-131 to -242 bp) or distal (-2098 to -1983 bp) regions of the human CEBPB promoter. We observed AR binding to the proximal but not the distal region ( Figure 3a) . Next, CEBPB-luc, containing proximal promoter region (−888 to +64) linked to a luciferase reporter, was co-transfected into LNCaP or DU145 PC cells with CMV-β-galactosidase as internal control. Reproducibly, luciferase activity significantly decreased by 2.5-fold in LNCaP cells cultured with 1 nM R1881 for 24 hrs compared with vehicle control (Figure 3b ). This effect on CEBPB promoter activation was mediated by the AR as R1881 did not reduce luciferase activity in similarly transfected DU145 cells which lack AR. Treatment of LNCaP cells with bicalutamide for 4 hours induced acetylation of histone H3 bound to the CEBPB proximal promoter, whereas culture with dihydrotestosterone (DHT) suppressed this mark of active transcription (Figure 3c ). Importantly, we did not observe significant changes in the half-life of CEBPB RNA in response to bicalutamide, indicating that the stability of CEBPB transcripts was unaffected (Figure 3d ). Collectively, these results show that the AR suppresses transcription of CEBPB.
Ectopic expression of C/EBPβ suppresses LNCaP cell growth
Because C/EBPβ expression was inversely regulated by AR activity, an essential signal for PC cell growth, we next evaluated whether ectopic expression induces growth arrest similar to androgen deprivation. C/EBPβ was inducibly expressed in LNCaP cells using the Tetregulated transposon-based piggyBac vector 29 and cells with stable integration of the transgene or an empty vector (TRE) control were selected by puromycin (2 mg/ml). Treatment of LNCaP PBCEBPB cells with doxycycline for 5 days induced an increase in the expression of C/EBPβ 2.5-fold (Figure 4a ), similar to the increase seen in LNCaP cells cultured in enzalutamide. C/EBPβ forced expression was associated with increased levels of the cell cycle inhibitors p16 INK4A and p15 INK4B and a flattened morphology (Figure 4a, 4b ). Next, we tested the effect of C/EBPβ overexpression on LNCaP cell proliferation. Equal numbers of LNCaP PB-CEBPB or PB-TRE control cells were seeded in doxycycline containing media and enumerated after 3 and 5 days. Ectopic C/EBPβ expression resulted in a significant 2.3-fold decreased rate of proliferation (figure 4c) and a significantly increased number of Ki67 negative cells 5 days after doxycycline treatment (figure 4d) without increased cell death ( figure 4e ). These data demonstrate that elevated levels of C/EBPβ are sufficient to suppress the growth of androgen-sensitive PC cells.
C/EBPβ is required for complete maintenance of androgen deprivation induced growth arrest Persistence of PC cells under androgen-deprived conditions is an initial step towards development of castration resistant growth. Upon androgen deprivation LNCaP cells undergo cell cycle arrest and enter a senescent state. 5 -7 Importantly, androgen deprivationinduced senescence is only partly reversible and cells continue to display senescence markers and poor proliferation after re-exposure to androgen. 6 Because C/EBPβ upregulation was associated with androgen deprivation and its expression sufficient to suppress LNCaP proliferation, we next targeted C/EBPβ to test its function in androgendeprivation-induced growth arrest. We utilized two independent methods: inducible shRNA and transcription activator-like effector nucleases (TALENs). 30 , 31 We designed a pair of TALENs to target the CEBPB gene, transfected LNCaP cells, and screened individual clones for C/EBPβ expression. Subclone 6, was identified as having CEBPB knockdown (presumably due to incomplete targeting of all alleles in the polyploid LNCaP cells) ( Figure  5a ), and used in our subsequent experiments. A complete stable deletion of all CEBPB alleles could not be achieved, suggesting C/EBPβ plays a critical role for cell survival. As control we employed subclone 1 in which C/EBPβ expression is similar to that observed in parental cells. In addition, C/EBPβ expression was effectively knocked down in LNCaP cells utilizing a doxycycline inducible shRNA against CEBPB (shCEBPB) compared with a nontargeting vector control (shNTV) (Figure 5b ). We used flow cytometry to investigate the effect of C/EBPβ depletion on PC cell cycle distribution ( Figure 5c ). For these studies we employed cells expressing the inducible shRNA as stable deletion of C/EBPβ via TALEN required adaptation to low C/EBPβ levels. Cells expressing shCEBPB or shNTV both went into G1 cell cycle arrest when cultured in androgen depleted media (ADM) (Figure 5c ). Charcoal stripped FBS lacks androgen and multiple other growth factors. To define the specific effect of androgen-depletion, LNCaP cells harboring shNTV or shCEBPB were precultured with doxycycline and bicalutamide, enzalutimide, or vehicle for 4 days, and subsequently re-plated at equal numbers in ARM without inhibitors ( Figure 6a ). In contrast to shNTV cells which demonstrated 2-fold decreased recovery, CEBPB depleted cells completely recovered their proliferation once released from AR-inhibition ( Figure 6c ). To better reflect recovery and adjust for the different proliferation rate in ARM of shCEBP compared to shNTV cells, we also plotted these data as a ratio of growth of cells precultured in ADM, bicalutamide, or enzalutimide to cells pre-cultured in ARM (Figure 6d ). This normalization highlights the recovery of proliferation of shCEBPB compared to shNTV cells in each experiment, indicating that C/EBPβ is required for maintenance of complete growth arrest induced by androgen deprivation and its suppression alleviates the phenotype, at least in part.
C/EBPβ elevation induces senescence
Because C/EBPβ seemed to play a role in maintaining growth arrest following androgen deprivation, we next evaluated whether over-expression of C/EBPβ was sufficient to induce senescence in LNCaP cells. Senescent cells are characterized by an increase in cell volume, granularity and lysosomal mass indicated by senescence associated β-galactosidase (SA-β-gal) activity. 32 Compared to control PB-TRE, PB-CEBPB cells had a significantly increase in the number SA-β-gal positive cells and the level of cell granularity, as assessed by side scatter, (Figures 7a and 7b) . Expression of several secreted gene products is elevated in senescent cells and is referred to as the senescence associated secretory phenotype (SASP). 24 Release of these secreted factors promotes paracrine growth arrest, and C/EBPβ was shown to be central to induction of SASP genes. 25 , 33 , 34 Accordingly, overexpression of C/EBPβ led to a significant increase in the transcript levels of two SASP-associated genes, IL8 and IGFBP3 (Figure 7c ). Similarly, we observed increased IGFBP3 and IL8 levels upon androgen deprivation, which was abrogated by either CEBPB shRNA or TALEN targeting (Figures 7d and 7e ). Another feature of senescent cells is accumulation of tightly packed heterochromatin foci (HF) characterized by increased di-or trimethylated histone 3 on lysine 9 (H3K9me2, H3K9me3). 35 When cultured in ADM, LNCaP-shNTV cells display a 2-fold increase in the number of HF positive cells. In contrast, we did not observe an increase in HF in shCEBPB cells cultured under similar conditions (Figure 7f ). Senescent cells exit cell cycle, and stain negative for Ki67. A similar proportion of shNTV or shCEBPB cells expressed Ki67 in ARM. However, the proportion of Ki67-negative cells after one week of culture in ADM was 2-fold lower in cells lacking C/EBPβ (Figure 7g ). Together, these data indicate that in PC cells C/EBPβ is necessary for induction of senescence upon androgen-deprivation.
Cellular senescence engenders a pro-survival phenotype. Given rapid induction of C/EBPβ in the absence of AR signaling and its role in directing senescence, we evaluated whether targeting C/EBPβ synergizes with anti-androgen agents or chemotherapy in killing PC cells. Culture of LNCaP shNTV and shCEBPB in ADM (Figure 8a ) or exposing them to bicalutamide (Figure 8b ) increased the number of dead cells relative to ARM cultures. However, there was no difference in cell viability between shNTV and shCEBPB cells (Figure 8a and 8b) . However, after pre-culture in ADM, treatment with docetaxel or etoposide induced a significant 68% or 55% increase in cell death, respectively, in LNCaP cells harboring shCEBPB compared with shNTV ( Figure 8c ). Together, these data demonstrate that C/EBPβ promotes a pro-survival, drug-resistant phenotype during androgen deprivation.
Discussion
Accumulating evidence points to a strong connection between senescence and tumor progression. 23 , 24 , 36 Oncogene induced senescence promotes the eventual emergence of subpopulations of aggressive, malignant cells and thus may be considered a tumor promoting state. In PC, androgen deprivation induced senescence promotes the development of tumor progression and resistance to apoptosis, 5 fostering the emergence of cancer initiating cells. 37 Increased numbers of senescent cells have been observed in tissue sections from tumors in patients that had been treated with neoadjuvant androgen deprivation therapy. 7 Also, cellular senescence induced by androgen deprivation dramatically increases reactive oxygen species and DNA double-strand breaks, and leads to the outgrowth of hormone-refractory populations in cultured LNCaP cells. 5 Our data demonstrate that inhibition of AR leads to rapid upregulation of CEBPB RNA, loss of AR interaction with the CEBPB promoter, and increased promoter H3K acetylation. To our knowledge, this is the first demonstration that CEBPB is a direct AR transcriptional repressive target. This observation is consistent with previous reports showing that AR can inhibit gene expression through interaction with transcriptional co-repressors at proximal promoter regions. 40 , 4142 Derepression of CEBPB occurs within 4 hours of exposure to antiandrogens. Conversely, treatment with AR agonist R1881 results in diminished expression of C/EBPβ and suppression of the activity of a CEBPB promoter luciferase reporter.
Accordingly, exposure to DHT leads to a decrease in activating AcH3 histone marks on the promoter. These findings indicate that AR suppresses CEBPB expression directly through regulation of the promoter. Examination of the CEBPB promoter sequence did not identify an androgen response element (ARE), suggesting indirect binding of AR. In other contexts, AR directly interacts with Sp1 to regulate gene expression in the absence of an ARE making Sp1 a potential mediator of AR regulation of CEBPB. 43 , 44 Treatment of LNCaP cells with anti-androgens or culture in hormone-depleted media leads to G1 arrest and cellular senescence. PC cells require AR signaling for transition from G1 to S and accordingly we did not observe continued proliferation of cells that had been cultured in hormone depleted media or with anti-androgens regardless of CEBPB knockdown.
Androgen deprivation induced senescence had a profound long-lived effect on PC cell proliferation in the presence of normal C/EBPβ levels even after reintroduction of androgens, as previously observed. 6 We found that after androgen deprivation, C/EBPβ deficiency allowed LNCaP cells to resume proliferation when re-seeded in ARM. Thus, C/ EBPβ plays an important role in the complete maintenance of senescent growth arrest induced by androgen deprivation. Overall, C/EBPβ promotes PC senescence and thereby potentially chemo-resistance and progression to castration-resistant growth through multiple transcriptional targets during androgen deprivation therapy (Figure 8d ).
Our delineation of CEBPB upregulation in human hormone-refractory PC further support the concept that C/EBPβ-dependent induction of senescence during androgen blockade promotes castration-resistant progression by providing the opportunity to respond the selective pressure of anti-androgen therapy. Importantly, these data indicate the potential utility of targeting C/EBPβ in combination with androgen deprivation for novel PC therapy.
Materials and Methods
Cell lines and plasmids
LNCaP cells were maintained in RPMI media without phenol red with 10% heat inactivated fetal bovine serum (HI-FBS) (Hyclone) supplemented with penicilin/streptomycin. LAPC4 cells were maintained in Iscove's modified Dulbecco's media (IMDM) supplemented with 15% HI-FBS, 1 nM DHT, and penicillin/streptomycin. DU145 cells were maintained in RPMI with 10% HI-FBS, and 293T cells were cultured in Dulbecco modified Eagle medium (DMEM) with 10% HI-FBS. Cells were grown in a humidified incubator maintained at 37°C with 5% CO 2 . Cells were split 1:4 and were used until passage 40. Cells transduced with pTRIPZ-shRNA or transfected with pPB-TRE-Puro were maintained in tetracyclinescreened FBS (Hyclone). For androgen deprivation cells were cultured in phenol red-free media supplemented with 10% charcoal-stripped-FBS (csFBS) (Hyclone). Androgen receptor was blocked using enazlutamide (Selleckchem Houston, TX USA) or bicalutamide (Sigma-Aldrich St. Louis, MO USA).
pTRIPZ-shRNA (Open Biosystems) lentiviral vectors were generated as described 58 and stably transduced cells were selected with puromycin (2 μg/ml) after 48 hrs. Expression of shRNA was induced by treating cells with 200 ng/ml doxycycline, replaced every 48 hrs and confirmed by fluorescence microscopy detection of RFP.
The pPB-TRE-Puro plasmid (kindly provided by Jolene Ooi and Pentao Liu) contains a multiple cloning site downstream of a TRE element, and a CAG promoter upstream of rtTA, IRES, and apuromycin resistance gene. The mouse Cebpb ORF including the 3'UTR (1-1400) was ligated as BamHI/NotI fragment into the BglII/NotI digested pPB-TRE-Puro plasmid 29 to generate the pPB-CEBPB which was confirmed by sequencing. Stable PB-TRE and PB-CEBPB cell lines were generated by transfecting equal parts pCMVhyperpiggybase and piggybac vectors by lipofection.
Western Blotting
Protein samples from whole cell lysates and nuclear extracts were prepared and subjected to Western blotting as previously described. 59 After blocking with Odyssey blocking buffer 
Quantitative real-time PCR
Total RNA was isolated from cells and first strand cDNA was synthesized as previously described. 58 β-actin transcript was used as a reference to normalize samples and relative expression was calculated as described. 58 Each sample was assayed in triplicates and each experiment was repeated at least three times. Oligonucleotides were custom ordered from Sigma-Aldrich, and their sequences are presented in Table 1 .
Luciferase reporter assays
Using PCR, a DNA fragment from -888 to +64 base pairs (bp) relative to the initiation of transcription (Ensembl database) of the human CEBPB promoter was cloned as a BamHI/ MluI fragment into BglII/MluI digested pGL3-luciferase reporter vector (Promega, Medison,WI USA) to generate CEBPB-Luc that was confirmed by Sanger sequencing. LNCaP or DU145 cells were seeded in 6-well plates and transfected using Lipofectamine 2000. Each well was cotransfected with 1.4 μg of the reporter plasmid and 10 ng of CMV-β-galactosidase as an internal control. Twenty four hours after transfection cells were treated with vehicle (0.01% ethanol) or the androgen agonist R1881 (Sigma-Aldrich) and after additional 24 hrs lysed (Reporter Lysis Buffer, Promega) and assayed for luciferase and β-galactosidase activity. Fold activation relative to the vehicle treated cells after correction for β-galactosidase activity was determined. Lysates from non-transfected cells were used as baseline.
TALEN construction and CEBPB gene editing
TALEN DNA constructs targeting the human CEBPB ORF were constructed using the Golden Gate Talen assembly kit (Addgene. Cambridge, MA USA). 30 Targeting sequences were designed using the Cornell University TAL Effector Nucleotide Targeter 2.0 web based software. Golden Gate assembly of the repeat-variable di-residue sequence was performed according to the manufacturer's instructions and the completed TALEN pairs were ligated into the pTAL3 vector. The complete TALEN ORF including the repeat-variable and FokI domains was excised using XhoI and ApaI restriction endonuceases and ligated into the pcDNA3.1(+) vector. LNCaP cells cotransfected with TALEN expression vectors targeting CEBPB were seeded in 96 well dishes, and individual clones were screened for C/EBPβ expression by Western blotting.
DNA content analysis and Flow cytometry
Cell cycle analysis by DNA content was performed as previously described. 60 Ki67 expressing cells were identified by flow cytometry using APC-anti-Ki67 antibody (BioLegend, San Diego, CA). Flow cytometry analysis was performed using a BD FACSCalibur machine (BD Biosciences), Sub-cellular debris and dead cells were gated out and singlet discrimination was performed by gating on FL2-A and FL2-W channels and data were interpreted using FloJo Cytometric Analytical software (TreeStar).
Chromatin immunoprecipitation (ChIP)
5E6 LNCaP cells were used in each ChIP reaction as previously described, 58 using antibodies against C/EBPβ, AR, rabbit IgG (Santa Cruz Biotechnology), or acetylated histone H3 (06-599) (Millipore, Billerica, MA USA). DNA fragments corresponding to the promoters of interest were detected by PCR using the primers presented in Table 1 .
Cell viability and proliferation assays
Viability was determined using the WST-1 assay (Roche). Briefly, cells were seeded into 96 well plates, allowed to adhere for 48 hrs and then treated for an additional 48 hours. WST-1 reagent (Roche) was directly added to the wells and after incubation absorbance was read at 450 nm using a BioRad Microplate Reader Model 680. The 670 nm reference absorbance and readings from blank wells containing only cell culture media and DMSO (vehicle) were subtracted from experimental wells. Relative viability was determined by dividing absorbance readings from vehicle treated wells. For cell proliferation, LNCaP cells were grown for 7 days in growth or hormone-depleted media. Cells were trypsinized, stained with Trypan blue dye and viable cells were enumerated using a hemocytometer. 1.5E5 cells per well were seeded into 6-well plates in ARM. After 5 days cells were similarly enumerated.
SA-β-Gal Chromogenic Assay
SA-β-Gal positive cells were stained using the chromogenic assay as described. 61 Five random fields of view were imaged on a Leica E600 microscope by brightfield microscopy at 200x magnification. Positive cells were identified as those containing blue precipitate throughout the cytoplasm.
Immunofluorescent staining and SAHF-quantification
LNCaP cells were seeded onto Poly-D-lysine coated glass coverslips and following treatment were fixed in 4% paraformaldehyde. Cells were washed and incubated in permeabilization buffer (TBS, 2% BSA, 0.5% Triton-X 100, 0.1% sodium azide). After blocking, cells were incubated with anti-di/trimethyl H3K9 (1:250, Cell Signaling Technology Danvers, MA USA), washed and incubated with goat anti-mouse-Alexafluor 488 conjugated secondary antibody (Life Technologies). Cells were washed and mounted on glass slides for analysis by fluorescence microscopy. SAHF were imaged on a Leica E800 fluorescence microscope with a CCD camera and imaged at 630X magnification with an oil immersion objective. Fluorescent micrographs of SAHF from 6-7 random fields of view were quantified using ImageJ (National Institutes of Health Bethesda, MD USA). Intensely stained nuclei with multiple fluorescent foci that colocalized with DAPI staining were counted as positive cells containing SAHF.
Statistical analysis
Statistical comparison of two groups of samples was conducted using the Student's t-test.
Comparisons of multiple groups of samples was performed using the analysis of variance followed by multiple comparisons with the Student's t-test and the Holm-Bonferonni
Correction (α/(n-k+1), where n = number of comparisons and k = rank of p-value). 
